About Knovea Pharmaceutical Private Limited
Data last updated: 06 February 2026
Knovea Pharmaceutical Private Limited is a private limited company based in Indore, Madhya Pradesh, India, a subsidiary of Symbiotec Pharmalab Private Limited. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 17 February 2020, the company has been in operation for over 6 years.
Registered with ROC Gwalior under CIN U24110MP2020PTC050978.
Capital: an authorised share capital of ₹10 Cr and a paid-up capital of ₹1 Cr. It is led by directors including Sumit Gupta and Rohit Brijmohan Mantri.
Last AGM: 26 September 2025. Financial statements filed for year ended 31 March 2025. Office: Kh. No.385/2 Vill. Pigdamber Rau, Indore, Madhya Pradesh, India – 453331.
As per the financials filed for FY 2025, the company reported a revenue of ₹62.7 Lakh, reflecting significant growth compared to the previous year.
The company has a workforce of approximately 115 employees as per the latest available data. It operates as a subsidiary of Symbiotec Pharmalab Private Limited.
The company is associated with 2 brands - Knovea, Symbiotec. As per MCA filings, the company has open charges of ₹157.22 Cr and satisfied charges of ₹51.5 Cr on record.
For more details, the company can be reached via its website knovea.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media**************
-
Registered AddressKh. No.385/2 Vill. Pigdamber Rau, Indore, Madhya Pradesh, India – 453331
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Associated Brands with Knovea Pharmaceutical Private Limited
Knovea Pharmaceutical Private Limited operates two associated brands: Knovea and Symbiotec. These brands represent Knovea Pharmaceutical Private Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Non-sterile steroid hormone-based APIs and intermediates are manufactured. | symbiotec.in | |
| Pharmaceutical manufacturing, R&D, and quality services in India. | knovea.com |
Competitors & Alternatives of Knovea Pharmaceutical Private Limited
Brands and companies operating in the same space as Knovea Pharmaceutical Private Limited include Laurus Labs, Sterling Pharma Solutions, Provepharm Life Solutions and 4 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Laurus Labs
|
Pharmaceutical and biotechnology company | Hyderabad, India, India | 2005 |
Sterling Pharma Solutions
|
Contract development, manufacturing, and analytical services for APIs are offered. | Dudley, United Kingdom, United Kingdom | 2016 |
Provepharm Life Solutions
|
APIs and drug products are developed and valorized in pharmaceuticals. | Marseille, France, France | 1998 |
Apicore
|
APIs are manufactured and custom synthesis services are provided. | Somerset, United States, United States | 2004 |
SeQuent
|
APIs are developed and manufactured for therapeutic areas. | Bengaluru, India, India | 2002 |
Jubilant Pharma
|
Pharmaceuticals, APIs, and radiopharmaceuticals are manufactured by the company. | Noida, India, India | 1978 |
Bellen Chemistry
|
APIs and intermediates are researched and manufactured, specializing in heterocycles. | Beijing, China, China | 2007 |
Business Activity of Knovea Pharmaceutical Private Limited
Knovea Pharmaceutical Private Limited is engaged in principal business activities including manufacturing and professional, scientific and technical, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products, scientific research and development. The company has 2 registered principal business activity segments, demonstrating its operational diversity and market reach.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
| M | Professional, Scientific and Technical | M5 | Scientific research and development | ********* |
Auditor Details of Knovea Pharmaceutical Private Limited
Knovea Pharmaceutical Private Limited is audited by S R B C & Co. LLP for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| S R B C & Co. LLP | blur-value | blur-value | blur-value |
Board of Directors of Knovea Pharmaceutical Private Limited
Knovea Pharmaceutical Private Limited is currently managed by 4 directors, with 1 former director having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Sumit Gupta
Also directs:
Indilyfe Sponsor Llp, Sunways Rohto Pharmaceutical Private Limited
|
Nominee Director | 17 Feb 2020 | 6 Years 4 Months | Current |
|
Rohit Brijmohan Mantri
Also directs:
Symbiotec Biologics Private Limited, Symbiotec Zenfold Private Limited, Symbiotec Pharmalab Limited and 5 more
|
Nominee Director | 17 Feb 2020 | 6 Years 4 Months | Current |
|
Buggana Hariharnath
Also directs:
Symbiotec Zenfold Private Limited, Symbiotec Pharmalab Limited, Invascent Advisory Services India Llp and 5 more
|
Nominee Director | 16 Sep 2024 | 1 Years 9 Months | Current |
| Anil Kumar Satwani | Director | 17 Feb 2020 | 6 Years 4 Months | Current |
Financials of Knovea Pharmaceutical Private Limited FY 2025 filings available
Knovea Pharmaceutical Private Limited reported revenue of ₹62.7 Lakh (up 321% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Knovea Pharmaceutical Private Limited
As of FY 2023, Knovea Pharmaceutical Private Limited's shareholding pattern shows 100.00% by promoters. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Charges & Borrowings of Knovea Pharmaceutical Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 01 Sep 2022 | Sbicap Trustee Company Limited | ₹157.22 Cr | Open |
| 26 Sep 2024 | Axis Bank Limited | ₹18 Cr | Satisfied |
| 23 Sep 2021 | Axis Bank Limited | ₹33.5 Cr | Satisfied |
Total charge records: 3 View all charges
Employees and EPFO Compliance at Knovea Pharmaceutical Private Limited
Knovea Pharmaceutical Private Limited has a workforce of 115 employees as of Apr 05, 2024.
Employee Count & EPFO Data of Knovea Pharmaceutical Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Knovea Pharmaceutical Private Limited
GSTIN & GST Filing Data of Knovea Pharmaceutical Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Knovea Pharmaceutical Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Knovea Pharmaceutical Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Knovea Pharmaceutical Private Limited
MSME Payment Delays by Knovea Pharmaceutical Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Knovea Pharmaceutical Private Limited
Subsidiaries & Group Companies of Knovea Pharmaceutical Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Knovea Pharmaceutical Private Limited with ownership details.
MCA Filings & Documents of Knovea Pharmaceutical Private Limited
MCA Filings & Documents of Knovea Pharmaceutical Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Knovea Pharmaceutical Private Limited
Frequently Asked Questions about Knovea Pharmaceutical Private Limited
Knovea Pharmaceutical Private Limited is an active private limited company in the pharma sector based in Indore, Madhya Pradesh, India. It was incorporated on 17 February 2020 (6+ years old) and is registered under CIN U24110MP2020PTC050978. The company has 115 employees.
Knovea Pharmaceutical Private Limited reported revenue of ₹62.7 Lakh for FY 2025 (up 321.00% YoY).
The current directors of Knovea Pharmaceutical Private Limited are:
The primary industry of Knovea Pharmaceutical Private Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Knovea Pharmaceutical Private Limited can be reached at the registered office: Kh. No.3852 Vill. Pigdamber Rau, Indore, Madhya Pradesh, India – 453331, or through the website knovea.com.
The authorised capital is ₹10 Cr, and the paid-up capital is ₹1 Cr.